NEW YORK (GenomeWeb) – As part of an upcoming phase III study of its investigational non-alcoholic steatohepatitis (NASH) drug elafibranor, French biopharmaceutical firm Genfit is aiming to validate a diagnostic method that uses blood-based biomarkers to identify patients with the disease who are candidates for treatment.

While the test won't be used to select trial participants, it is expected to launch at the same time as elafibranor and help clinicians know which patients should receive therapy without the need for liver biopsy.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb or 360Dx Premium member?
Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers in China have generated mouse pups from same-sex parents, according to Scientific American.

Two research teams find a role for PIEZO2 in touch sensitivity after injury and inflammation.

The South China Morning Post reports that Hong Kong plans to add HK$20 billion (US$2.6 billion) to a research endowment.

In Science this week: open genetic genealogy databases can lead to the identification of individuals who have not sought testing, and more.